Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
š¼
SK
or Search
SIGN UP
SIGN IN
ENTITY
Icure Pharm Inc (175250 KS)
Watchlist
22
Analysis
Health Care
ā¢
South Korea
Icure Pharm. Inc. manufactures and distributes biopharmaceuticals. The Company produces drugs, cosmetics, and other biopharmaceuticals. Icure Pharm markets its products worldwide.
more
Watchlist
All
Insights
Primers
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
ā¢
SIMMTECH Co Ltd
ā¢
27 Apr 2021 13:33
KOSDAQ150 Index Rebalance Preview: 15 Potential Changes; Big Impact on Deletions
We see 15 potential changes to the KOSDAQ150 Index at the June review. With short selling resuming on 3 May, the inclusions could outperform the...
Brian Freitas
Follow
650 Views
Share
bullish
ā¢
Icure Pharm Inc
ā¢
16 Feb 2021 04:38
KOSDAQ150 Index Rebalance Preview: Expected Inclusions Continue to Move Higher
We see 13 potential inclusions and exclusions at the June review of the KOSDAQ150 Index. After giving up some gains vs the expected deletes and the...
Brian Freitas
Follow
624 Views
Share
bullish
ā¢
Doosan Tesna Inc.
ā¢
15 Dec 2020 06:32
KOSDAQ150 Index Rebalance Preview: Lots of Changes Expected Already; More to Come
Less than a third of the way through the review period, we see 14 potential inclusions and exclusions from the KOSDAQ150 index. The resumption of...
Brian Freitas
Follow
590 Views
Share
bearish
ā¢
Icure Pharm Inc
ā¢
10 Jul 2018 08:45
Icure Pharm (175250 KS): Post IPO Short Selling Opportunity Checkup
Icure Pharm Inc (175250 KS)Ā IPO price was set at ā©65,000. This is even higher than the upper end of the indicative price band, ā©44,000 - 55,000....
Sanghyun Park
Follow
605 Views
Share
bullish
ā¢
Icure Pharm Inc
ā¢
02 Jun 2018 11:48
Icure Pharm IPO Summary - Front Runner of Dementia Patch Development Race
Icure Pharm Inc (175250 KS)Ā will offer a total ofĀ 1,200,000 shares (100% new rights offering) atĀ ā©44,000 - ā©55,000 which gives a market cap of...
Sanghyun Park
Follow
452 Views
Share
First
Previous
1
2
3
4
5
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
How Smartkarma Compares
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright Ā© 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4
x